
Cinizia Valzania

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1565100/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Single-photon cardiac imaging in patients with cardiac implantable electrical devices. Journal of Nuclear Cardiology, 2022, 29, 633-641.	2.1	4
2	Three-dimensional left ventricular mechanical dyssynchrony assessed by myocardial perfusion gated-SPECT: Is there a role in cardiac resynchronization therapy?. Journal of Nuclear Cardiology, 2022, 29, 1626-1628.	2.1	1
3	Ten-year follow-up of cardiac resynchronization therapy patients with non-ischemic dilated cardiomyopathy assessed by radionuclide angiography: a single-center cohort study. Journal of Interventional Cardiac Electrophysiology, 2022, , .	1.3	0
4	Axillary vein access for antiarrhythmic cardiac device implantation: a literature review. Journal of Cardiovascular Medicine, 2021, 22, 237-245.	1.5	5
5	Cardiovascular Imaging Applications in Clinical Management of Patients Treated with Cardiac Resynchronization Therapy. Hearts, 2020, 1, 166-180.	0.9	2
6	Herpes zoster in COVIDâ€19â€positive patients. International Journal of Dermatology, 2020, 59, 1028-1029.	1.0	93
7	Cardiac implantable electrical devices in patients with hypertrophic cardiomyopathy: single center implant data extracted from the Swedish pacemaker and ICD registry. Scandinavian Cardiovascular Journal, 2020, 54, 239-247.	1.2	6
8	Effects of cardiac resynchronization therapy on right ventricular function during rest and exercise, as assessed by radionuclide angiography, and on NT-proBNP levels. Journal of Nuclear Cardiology, 2019, 26, 123-132.	2.1	8
9	Role of cardiovascular imaging in cardiac resynchronization therapy. Journal of Cardiovascular Medicine, 2018, 19, 211-222.	1.5	13
10	Five year trends (2008–2012) in cardiac implantable electrical device utilization in five European nations: a case study in cross-country comparisons using administrative databases. Europace, 2018, 20, 643-653.	1.7	20
11	Investigating Regional Variation of Cardiac Implantable Electrical Device Implant Rates in European Healthcare Systems: What Drives Differences?. Health Economics (United Kingdom), 2017, 26, 30-45.	1.7	24
12	Less is more: Can we achieve cardiac resynchronization with 2 leads only?. International Journal of Cardiology, 2017, 249, 184-190.	1.7	12
13	Implant rates of cardiac implantable electrical devices in Europe: A systematic literature review. Health Policy, 2016, 120, 1-15.	3.0	44
14	Effect of Cardiac Resynchronization Therapy on Left Atrial Size and Function as Expressed by Speckle Tracking 2-Dimensional Strain. American Journal of Cardiology, 2016, 118, 237-243.	1.6	21
15	Battery drain in daily practice and medium-term projections on longevity of cardioverter-defibrillators: an analysis from a remote monitoring database. Europace, 2016, 18, 1366-1373.	1.7	21
16	Non-valvular atrial fibrillation. Journal of Cardiovascular Medicine, 2015, 16, 491-496.	1.5	17
17	Current use of implantable electrical devices in Sweden: data from the Swedish pacemaker and implantable cardioverter-defibrillator registry. Europace, 2015, 17, 69-77.	1.7	94
18	Cardiac resynchronization therapy. Journal of Cardiovascular Medicine, 2014, 15, 269-272.	1.5	6

CINIZIA VALZANIA

#	Article	IF	CITATIONS
19	Cost-effectiveness of implantable cardioverter-defibrillator in today's world. Indian Heart Journal, 2014, 66, S101-S104.	O.5	15
20	Asymptomatic Lone Atrial Fibrillation - How can we Detect the Arrhythmia?. Current Pharmaceutical Design, 2014, 21, 659-666.	1.9	29
21	Acute changes in electromechanical parameters during different pacing configurations using a quadripolar left ventricular lead. Journal of Interventional Cardiac Electrophysiology, 2013, 38, 61-69.	1.3	10
22	Atrial Fibrillation in Patients with Cardiac Resynchronization Therapy: Clinical Management and Outcome. Journal of Atrial Fibrillation, 2013, 5, 748.	0.5	0
23	Metaâ€analysis of randomized controlled trials evaluating left ventricular vs. biventricular pacing in heart failure: effect on all ause mortality and hospitalizations. European Journal of Heart Failure, 2012, 14, 652-660.	7.1	45
24	Changes in global longitudinal strain during rest and exercise in patients treated with cardiac resynchronization therapy. Clinical Physiology and Functional Imaging, 2012, 32, 310-316.	1.2	4
25	Arrhythmia discrimination by physician and defibrillator: Importance of atrial channel. International Journal of Cardiology, 2012, 154, 134-140.	1.7	16
26	QRS pattern and improvement in right and left ventricular function after cardiac resynchronization therapy: a radionuclide study. BMC Cardiovascular Disorders, 2012, 12, 27.	1.7	5
27	Longâ€Term RV Threshold Behavior by Automated Measurements: Safety is the Standpoint of Pacemaker Longevity!. PACE - Pacing and Clinical Electrophysiology, 2011, 34, 89-95.	1.2	23
28	Management of Phrenic Stimulation in CRT Patients over the Long Term: Still an Unmet Need ?. PACE - Pacing and Clinical Electrophysiology, 2011, 34, 1201-1208.	1.2	21
29	Effects of cardiac resynchronization therapy on myocardial contractile reserve during exercise. European Journal of Heart Failure, 2011, 13, 406-411.	7.1	6
30	Radionuclide Angiographic Determination of Regional Left Ventricular Systolic Function During Rest and Exercise in Patients With Nonischemic Cardiomyopathy Treated With Cardiac Resynchronization Therapy. American Journal of Cardiology, 2010, 106, 389-394.	1.6	5
31	Role of drugs and devices in patients at risk of sudden cardiac death. Fundamental and Clinical Pharmacology, 2010, 24, 575-594.	1.9	15
32	Interventricular Delay Optimization: A Comparison among Three Different Echocardiographic Methods. Echocardiography, 2010, 27, 38-43.	0.9	7
33	Longâ€Term Followâ€Up of Patients with Syncope Evaluated by Headâ€Up Tilt Test. Annals of Noninvasive Electrocardiology, 2010, 15, 101-106.	1.1	7
34	Is cardiac resynchronization therapy cost-effective?. Europace, 2009, 11, v93-v97.	1.7	17
35	Phrenic Stimulation. Circulation: Arrhythmia and Electrophysiology, 2009, 2, 402-410.	4.8	114
36	Troponin I Rise After Pacemaker Implantation at the Time of "Universal Definition of Myocardial Infarction― American Journal of Cardiology, 2009, 103, 1061-1065.	1.6	11

3

CINIZIA VALZANIA

#	Article	IF	CITATIONS
37	Clinical implications of left superior vena cava persistence in candidates for pacemaker or cardioverter-defibrillator implantation. Heart and Vessels, 2009, 24, 142-146.	1.2	53
38	Multiple Vector Impedance Measurements During Biventricular Pacing: Feasibility and Possible Implications for Hemodynamic Monitoring. PACE - Pacing and Clinical Electrophysiology, 2009, 32, 1492-1500.	1.2	8
39	Automatic Verification of Ventricular Stimulation: Fusion Management Algorithm. PACE - Pacing and Clinical Electrophysiology, 2008, 31, 64-69.	1.2	7
40	Left Ventricular versus Biventricular Pacing: A Randomized Comparative Study Evaluating Midâ€Term Electromechanical and Clinical Effects. Echocardiography, 2008, 25, 141-148.	0.9	18
41	Telecardiology and Remote Monitoring of Implanted Electrical Devices: The Potential for Fresh Clinical Care Perspectives. Journal of General Internal Medicine, 2008, 23, 73-77.	2.6	50
42	Interventricular Delay Interval Optimization in Cardiac Resynchronization Therapy Guided by Echocardiography Versus Guided by Electrocardiographic QRS Interval Width. American Journal of Cardiology, 2008, 102, 1373-1377.	1.6	44
43	How to assess the efficacy of catheter ablation of atrial fibrillation?. European Heart Journal, 2008, 29, 2183-2184.	2.2	0
44	Cardiac resynchronization therapy during rest and exercise: comparison of two optimization methods. Europace, 2008, 10, 1161-1169.	1.7	36
45	Effects of cardiac resynchronization therapy on coronary blood flow: Evaluation by transthoracic Doppler echocardiographyâ~†. European Journal of Heart Failure, 2008, 10, 514-520.	7.1	17
46	Atrial fibrillation ablation: beyond electro-mechanical matters. European Heart Journal, 2008, 29, 2818-2819.	2.2	1
47	Potential of non-antiarrhythmic drugs to provide an innovative upstream approach to the pharmacological prevention of sudden cardiac death. Expert Opinion on Investigational Drugs, 2007, 16, 605-623.	4.1	16
48	Electromechanical effects of cardiac resynchronization therapy during rest and stress in patients with heart failure. European Journal of Heart Failure, 2007, 9, 644-650.	7.1	19
49	Effects of Cardiac Resynchronization Therapy on Diastolic Function: Evaluation by Radionuclide Angiography. PACE - Pacing and Clinical Electrophysiology, 2007, 30, S43-6.	1.2	2
50	How, Why, and When May Atrial Defibrillation Find a Specific Role in Implantable Devices? A Clinical Viewpoint. PACE - Pacing and Clinical Electrophysiology, 2007, 30, 422-433.	1.2	11
51	Plateau Waveform Shape Allows a Much Higher Patient Shock Energy Tolerance in AF Patients. Journal of Cardiovascular Electrophysiology, 2007, 18, 728-734.	1.7	6
52	Cardiac Resynchronization Therapy: Variations in Echo-Guided Optimized Atrioventricular and Interventricular Delays During Follow-Up. Echocardiography, 2007, 24, 933-939.	0.9	49
53	Outcome of cardioverter–defibrillator implant in patients with arrhythmogenic right ventricular cardiomyopathy. Heart and Vessels, 2007, 22, 184-192.	1.2	30
54	Cardiac resynchronization therapy in clinical practice: Need for electrical, mechanical, clinical and logistic synchronization. Journal of Interventional Cardiac Electrophysiology, 2007, 17, 215-224.	1.3	16

CINIZIA VALZANIA

#	Article	IF	CITATIONS
55	AB7-2. Heart Rhythm, 2006, 3, S13.	0.7	3
56	Electrocardiographic remodeling during cardiac resynchronization therapy. International Journal of Cardiology, 2006, 108, 165-170.	1.7	29
57	Acute and chronic haemodynamic effects of biventricular pacing and of switching to different pacing modalities in heart failure patients. International Journal of Cardiology, 2006, 110, 318-323.	1.7	14
58	Short QT syndrome and arrhythmogenic cardiac diseases in the young: the challenge of implantable cardioverter-defibrillator therapy for children. European Heart Journal, 2006, 27, 2382-2384.	2.2	24
59	Cardiac Resynchronization Therapy:. PACE - Pacing and Clinical Electrophysiology, 2005, 28, S11-4.	1.2	26
60	Atrial Fibrillation in Patients with a Dual Defibrillator: Characteristics of Spontaneous and Induced Episodes and Effect of Ventricular Tachyarrhythmia Induction. Journal of Cardiovascular Electrophysiology, 2005, 16, 974-980.	1.7	3
61	Mechanisms of pain associated with internal defibrillation shocks: Results of a randomized study of shock waveform. Heart Rhythm, 2005, 2, 708-713.	0.7	20
62	P wave dispersion and short-term vs. late atrial fibrillation recurrences after cardioversion. International Journal of Cardiology, 2005, 101, 355-361.	1.7	54
63	Efficacy of internal cardioversion for chronic atrial fibrillation in patients with and without left ventricular dysfunction. International Journal of Cardiology, 2004, 95, 43-47.	1.7	10
64	Increase in QT/QTc dispersion after low energy cardioversion of chronic persistent atrial fibrillation. International Journal of Cardiology, 2004, 95, 245-250.	1.7	9